Literature DB >> 29663429

Remote Cherenkov imaging-based quality assurance of a magnetic resonance image-guided radiotherapy system.

Jacqueline M Andreozzi1, Karen E Mooney2, Petr Brůža1, Austen Curcuru2, David J Gladstone3,4, Brian W Pogue5, Olga Green2.   

Abstract

PURPOSE: Tools to perform regular quality assurance of magnetic resonance image-guided radiotherapy (MRIgRT) systems should ideally be independent of interference from the magnetic fields. Remotely acquired optical Cherenkov imaging-based dosimetry measurements in water were investigated for this purpose, comparing measures of dose accuracy, temporal dynamics, and overall integrated IMRT delivery.
METHODS: A 40 × 30.5 × 37.5 cm3 water tank doped with 1 g/L of quinine sulfate was imaged using an intensified charge-coupled device (ICCD) to capture the Cherenkov emission while being irradiated by a commercial MRIgRT system (ViewRay™). The ICCD was placed down-bore at the end of the couch, 4 m from treatment isocenter and behind the 5-Gauss line of the 0.35-T MRI. After establishing optimal camera acquisition settings, square beams of increasing size (4.2 × 4.2 cm2 , 10.5 × 10.5 cm2 , and 14.7 × 14.7 cm2 ) were imaged at 0.93 frames per second, from an individual cobalt-60 treatment head, to develop projection measures related to percent depth dose (PDD) curves and cross beam profiles (CPB). These Cherenkov-derived measurements were compared to ionization chamber (IC) and radiographic film dosimetry data, as well as simulation data from the treatment planning system (TPS). An intensity-modulated radiotherapy (IMRT) commissioning plan from AAPM TG-119 (C4:C-Shape) was also imaged at 2.1 frames per second, and the single linear sum image from 509 s of plan delivery was compared to the dose volume prediction generated by the TPS using gamma index analysis.
RESULTS: Analysis of standardized test target images (1024 × 1024 pixels) yielded a pixel resolution of 0.37 mm/pixel. The beam width measured from the Cherenkov image-generated projection CBPs was within 1 mm accuracy when compared to film measurements for all beams. The 502 point measurements (i.e., pixels) of the Cherenkov image-based projection percent depth dose curves (pPDDs) were compared to pPDDs simulated by the treatment planning system (TPS), with an overall average error of 0.60%, 0.56%, and 0.65% for the 4.2, 10.5, and 14.7 cm square beams, respectively. The relationships between pPDDs and central axis PDDs derived from the TPS were used to apply a weighting factor to the Cherenkov pPDD, so that the Cherenkov data could be directly compared to IC PDDs (average error of -0.07%, 0.10%, and -0.01% for the same sized beams, respectively). Finally, the composite image of the TG-119 C4 treatment plan achieved a 95.1% passing rate using 4%/4 mm gamma index agreement criteria between Cherenkov intensity and TPS dose volume data.
CONCLUSIONS: This is the first examination of Cherenkov-generated pPDDs and pCBPs in an MR-IGRT system. Cherenkov imaging measurements were fast to acquire, and minimal error was observed overall. Cherenkov imaging also provided novel real-time data for IMRT QA. The strengths of this imaging are the rapid data capture ability providing real-time, high spatial resolution data, combined with the remote, noncontact nature of imaging. The biggest limitation of this method is the two-dimensional (2D) projection-based imaging of three-dimensional (3D) dose distributions through the transparent water tank.
© 2018 American Association of Physicists in Medicine.

Entities:  

Keywords:  Cerenkov; MR-IGRT; MRI guided radiation therapy; cobalt-60; viewray

Mesh:

Substances:

Year:  2018        PMID: 29663429     DOI: 10.1002/mp.12919

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

1.  Optical imaging provides rapid verification of static small beams, radiosurgery, and VMAT plans with millimeter resolution.

Authors:  Muhammad Ramish Ashraf; Petr Bruza; Brian W Pogue; Nathan Nelson; Benjamin B Williams; Lesley A Jarvis; David J Gladstone
Journal:  Med Phys       Date:  2019-10-04       Impact factor: 4.071

2.  Cherenkov-excited luminescence scanned imaging using scanned beam differencing and iterative deconvolution in dynamic plan radiation delivery in a human breast phantom geometry.

Authors:  Mengyu Jeremy Jia; Petr Bruza; Jacqueline M Andreozzi; Lesley A Jarvis; David J Gladstone; Brian W Pogue
Journal:  Med Phys       Date:  2019-05-18       Impact factor: 4.071

3.  Direct in-water radiation dose measurements using Cherenkov emission corrected signals from polarization imaging for a clinical radiotherapy application.

Authors:  Émily Cloutier; Luc Beaulieu; Louis Archambault
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

4.  Optical imaging method to quantify spatial dose variation due to the electron return effect in an MR-linac.

Authors:  Jacqueline M Andreozzi; Petr Brůža; Jochen Cammin; Brian W Pogue; David J Gladstone; Olga Green
Journal:  Med Phys       Date:  2019-12-25       Impact factor: 4.071

5.  Visual Isocenter Position Enhanced Review (VIPER): a Cherenkov imaging-based solution for MR-linac daily QA.

Authors:  Daniel A Alexander; Petr Bruza; Aris G Rassias; Jacqueline M Andreozzi; Brian W Pogue; Rongxiao Zhang; David J Gladstone
Journal:  Med Phys       Date:  2021-05-09       Impact factor: 4.506

Review 6.  Medical physics challenges in clinical MR-guided radiotherapy.

Authors:  Christopher Kurz; Giulia Buizza; Guillaume Landry; Florian Kamp; Moritz Rabe; Chiara Paganelli; Guido Baroni; Michael Reiner; Paul J Keall; Cornelis A T van den Berg; Marco Riboldi
Journal:  Radiat Oncol       Date:  2020-05-05       Impact factor: 3.481

7.  Head and neck radiotherapy on the MR linac: a multicenter planning challenge amongst MRIdian platform users.

Authors:  Madalyne Chamberlain; Jerome Krayenbuehl; Janita E van Timmeren; Lotte Wilke; Nicolaus Andratschke; Helena Garcia Schüler; Stephanie Tanadini-Lang; Matthias Guckenberger; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2021-04-23       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.